Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about a hair loss treatment regimen that does not include finasteride. Specific treatments used are not mentioned.

User shared 3-month hair loss progress using foam Minoxidil, finasteride, microneedling, and shampoos. They experienced side effects with oral Minoxidil but had success with topical treatments and finasteride.

Breezula shows promising hair growth results, with up to 539% increase in hair count compared to placebo, and regulatory submissions are planned in the US and EU. Users are cautiously optimistic, noting the potential for Breezula to replace finasteride by targeting DHT without systemic effects.

A US federal judge ruled that using patients' stem cells for medical treatments is not under FDA jurisdiction, potentially speeding up development of stem cell-based hair loss therapies. Some users are optimistic about increased research and development, while others express skepticism about the ruling's impact on safety and efficacy standards.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

The user is considering hair transplant clinics Vera, Smile, and Pure Line, with concerns about clinic reputation and effectiveness. They are seeking firsthand experiences and advice, with some users recommending against Smile and favoring Pure Line for its personalized approach.

Dermmatch is wind and water proof, but requires more hair to look good. Using both Dermmatch and hair fibers together can provide better coverage and a more natural look.

Everychem's solution, similar to PP405, has mixed results for hair regrowth, with some users reporting improvements and others seeing no change or worsening hair loss. Users are sharing experiences and updates to determine its effectiveness.

BlueMagic Clinic is praised for communication and follow-up, while Smile Hair Clinic is noted for consistent results and visible doctors. Both clinics have mixed reviews, with some users advising against them due to concerns about quality and aftercare.

The conversation is about a person's 6-week progress using 2.5 mg oral minoxidil, 0.5 mg dutasteride, weekly derma stamping at 1.5 mm, and rosemary oil for hair loss, with some initial shedding but no side effects. They are optimistic about future results.

The post and conversation are about using bimatoprost for hair regrowth, with the user seeking a higher concentration to enhance results. The user also discusses difficulties in sourcing the powder for personal use.

A dermatologist checked for hereditary hair loss using blood tests and plans to perform a trichogram. The user had slightly low Vitamin D3 levels, and the trichogram may help confirm androgenetic alopecia.

A user is seeking recommendations for dermatologists or hair clinics in the Greater Sacramento or Bay Area for exosome treatments, comparing topical application plus microneedling versus direct scalp injections. They are also asking for personal experiences and before-and-after photos.

12 companies having drugs or therapies in clinical trials during 2023, with various molecules and phases of trial; the probability that some may fail; and progress being made in the field.

Justin Trudeau's full head of hair at 53 is humorously attributed to unpredictable genetics and possible use of finasteride. The conversation jokes about a resemblance to Fidel Castro, suggesting genetic luck or treatment use.

The user applies a topical solution containing minoxidil, finasteride, dutasteride, retinoic acid, and hydrocortisone to address scalp inflammation and is considering adding cetirizine to the mix. They are calculating the correct amount of cetirizine to add to their formula and have paused this approach to retry oral minoxidil.

New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.

People are discussing their reactions if PP405 fails in phase 3 trials, with some expressing skepticism and others holding onto hope for future treatments like GT20029 and Breezula. Many mention continuing with existing treatments like minoxidil and finasteride, while others express disappointment and consider alternative solutions.

Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. Users share experiences and support, mentioning that many people face hair thinning.

The conversation is about the release timeline for clinical trial results and the availability of Breezula, a hair loss treatment. The user is not comfortable buying it as a research drug from China.

Many people become hyper-aware of hair loss in themselves and others, often leading to feelings of jealousy or self-consciousness. Treatments like finasteride, minoxidil, and dutasteride are commonly discussed as solutions to combat hair loss.

The conversation discusses organizing group buys and tracking progress for Kx-826 Pyrilutamide, a hair loss treatment. Participants express optimism about upcoming results and concerns about self-reporting bias.

Hair clinics prioritize making money over providing clear information. Effective treatments mentioned include oral finasteride and topical minoxidil.

PP405 is a promising new treatment for hair loss. It performs three actions in one, potentially offering a cure.

A 49-year-old is using minoxidil, finasteride, and supplement chews for hair growth, experiencing thick growth except on the top, and seeking advice on improving density. Suggestions include continuing treatment, considering additional options like oral minoxidil, ketoconazole shampoo, dermapen, and possibly a hair transplant, though cost is a concern.

The conversation discusses the potential of Replicel/Shiseido treatment for hair loss, questioning its effectiveness, whether it grows new follicles, and its market release timeline. It also compares Replicel to other competitors like Kyocera/RIKEN/Tsuji.

The conversation is about a person sharing before and after pictures of their hair loss treatment, which includes Minoxidil, Finasteride, and Dutasteride. They discuss their own hair loss, particularly the recession of their temporal points.

The conversation humorously discusses a visit to the Everychem laboratory, with a focus on hair loss treatments like Minoxidil, finasteride, and RU58841. The tone is satirical.

PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.